Second Sight Medical Products, Inc. (EYES) Upgraded by Zacks Investment Research to “Hold”

Second Sight Medical Products, Inc. (NASDAQ:EYES) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California. “

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Second Sight Medical Products in a report on Thursday, July 6th.

Shares of Second Sight Medical Products (NASDAQ EYES) traded up 2.193% during midday trading on Tuesday, reaching $1.165. The company’s stock had a trading volume of 1,119,426 shares. The company’s market capitalization is $66.17 million. Second Sight Medical Products has a 12-month low of $0.90 and a 12-month high of $3.51. The company’s 50-day moving average price is $1.14 and its 200 day moving average price is $1.18.

Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. Second Sight Medical Products had a negative return on equity of 168.49% and a negative net margin of 646.89%. The business had revenue of $2.24 million during the quarter, compared to analysts’ expectations of $1.43 million. During the same quarter last year, the business posted ($0.17) EPS. The business’s revenue was up 124.0% on a year-over-year basis. On average, equities research analysts forecast that Second Sight Medical Products will post ($0.55) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/10/10/second-sight-medical-products-inc-eyes-upgraded-by-zacks-investment-research-to-hold-2.html.

A hedge fund recently raised its stake in Second Sight Medical Products stock. BNP Paribas Arbitrage SA increased its position in Second Sight Medical Products, Inc. (NASDAQ:EYES) by 980,566.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 696,273 shares of the medical device company’s stock after purchasing an additional 696,202 shares during the quarter. BNP Paribas Arbitrage SA owned approximately 1.24% of Second Sight Medical Products worth $258,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 13.07% of the company’s stock.

About Second Sight Medical Products

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The

According to Zacks, “Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California. “

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Second Sight Medical Products in a report on Thursday, July 6th.

Shares of Second Sight Medical Products (NASDAQ EYES) traded up 2.193% during midday trading on Tuesday, reaching $1.165. The company’s stock had a trading volume of 1,119,426 shares. The company’s market capitalization is $66.17 million. Second Sight Medical Products has a 12-month low of $0.90 and a 12-month high of $3.51. The company’s 50-day moving average price is $1.14 and its 200 day moving average price is $1.18.

Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. Second Sight Medical Products had a negative return on equity of 168.49% and a negative net margin of 646.89%. The business had revenue of $2.24 million during the quarter, compared to analysts’ expectations of $1.43 million. During the same quarter last year, the business posted ($0.17) EPS. The business’s revenue was up 124.0% on a year-over-year basis. On average, equities research analysts forecast that Second Sight Medical Products will post ($0.55) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/10/10/second-sight-medical-products-inc-eyes-upgraded-by-zacks-investment-research-to-hold-2.html.

A hedge fund recently raised its stake in Second Sight Medical Products stock. BNP Paribas Arbitrage SA increased its position in Second Sight Medical Products, Inc. (NASDAQ:EYES) by 980,566.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 696,273 shares of the medical device company’s stock after purchasing an additional 696,202 shares during the quarter. BNP Paribas Arbitrage SA owned approximately 1.24% of Second Sight Medical Products worth $258,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 13.07% of the company’s stock.

About Second Sight Medical Products

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Receive News & Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply